In a xenograft model using HCT116 colon cancer cells, the PPARγ agonist troglitazone inhibited the development of tumors [168]; also, feeding troglitazone to rats [173] and mice [174] decreased the incidence of colitis, which is a risk factor for colon cancer development in humans, and formation of aberrant crypt foci, an early step in the development of colon carcinoma [172]. Here, PPARG is linked to colonic neoplasm.